Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.

Walker AM, Koro CE, Landon J.

Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):760-8. doi: 10.1002/pds.1598.

PMID:
18383443
2.

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.

PMID:
20110009
3.

Coronary heart disease outcomes in patients receiving antidiabetic agents.

McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.

Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25.

PMID:
17551989
4.

The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.

Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):504-12.

PMID:
17245800
6.

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

Diabetes Care. 2006 Feb;29(2):254-8.

PMID:
16443869
7.

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5.

PMID:
19194648
8.

Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.

Aquilante CL, Zhang W, McCollum M.

Curr Med Res Opin. 2007 Mar;23(3):489-94.

PMID:
17355730
9.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
10.

Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.

Balkrishnan R, Arondekar BV, Camacho FT, Shenolikar RA, Horblyuk R, Anderson RT.

Clin Ther. 2007 Jun;29(6 Pt 1):1306-15.

PMID:
18036392
11.

Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.

Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM.

Diabetes Care. 2005 Jul;28(7):1680-9.

PMID:
15983320
12.

Medical therapy for diabetes is associated with increased use of lower endoscopy.

Lewis JD, Capra AM, Achacoso NS, Ferrara A, Levin TR, Quesenberry CP Jr, Habel LA.

Pharmacoepidemiol Drug Saf. 2007 Nov;16(11):1195-202.

PMID:
17603822
13.

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.

Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM.

Circulation. 2005 Feb 8;111(5):583-90.

14.

A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.

Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G.

Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):769-81. doi: 10.1002/pds.1615.

PMID:
18613278
15.

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA.

Diabetes Care. 2005 Oct;28(10):2345-51.

PMID:
16186261
16.

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Johnson JA, Majumdar SR, Simpson SH, Toth EL.

Diabetes Care. 2002 Dec;25(12):2244-8.

PMID:
12453968
17.

Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study.

Horsdal HT, Johnsen SP, Søndergaard F, Jacobsen J, Thomsen RW, Schmitz O, Sørensen HT, Rungby J.

Diabetes Metab Res Rev. 2009 Sep;25(6):515-22. doi: 10.1002/dmrr.971.

PMID:
19459168
18.

Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.

Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, Kurnik D, Lomnicky Y, Kokia E, Halkin H.

J Clin Pharmacol. 2011 Feb;51(2):173-80. doi: 10.1177/0091270010368281. Epub 2010 May 19.

PMID:
20484611
19.

Rosiglitazone and myocardial infarction in patients previously prescribed metformin.

Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM.

PLoS One. 2009 Jun 27;4(6):e6080. doi: 10.1371/journal.pone.0006080. Erratum in: PLoS One. 2010;5(7). doi: 10.1371/annotation/3330720e-5520-4211-91f3-d3b3d20e9804.

20.

Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.

Gulliford M, Latinovic R.

Diabetes Metab Res Rev. 2004 May-Jun;20(3):239-45.

PMID:
15133756

Supplemental Content

Support Center